ADMA Biologics, Inc.’s (ADMA) shares skyrocketed 76.2% in the past three months compared with the industry’s growth of 9.6%. The stock also hit a new 52-week high of $19.34 on Sept. 9.The stupendous rally can be attributed to the company’s impressive performance year to date. Sales in the first half increased 61%. Last month, the company also raised its annual guidance for 2024 and 2025 revenues and net income, based on the continuous growth of its unique and proprietary immunoglobulin, Asceniv.ADMA Outperf ...